ACIU 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
ACIU 近期報酬表現
-6.74%
Ac immune sa
-0.77%
同產業平均
0.12%
S&P500
與 ACIU 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
BDTX | Black diamond therapeutics inc | 2 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
MURA | Mural oncology plc | - | 2 分 | - | - | 1 分 | |
BIIB | Biogen inc | 5 分 | 4 分 | 4 分 | 3 分 | 1 分 | |
ABOS | Acumen pharmaceuticals inc | - | 3 分 | 4 分 | 2 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 3 分 | 2 分 | 3 分 | 1 分 |
- BDTX Black diamond therapeutics inc價值 2 分趨勢 3 分波段 2 分籌碼 2 分股利 1 分查看更多
ACIU 公司資訊
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer's disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.